ATE2512T1 - Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung. - Google Patents

Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.

Info

Publication number
ATE2512T1
ATE2512T1 AT80107181T AT80107181T ATE2512T1 AT E2512 T1 ATE2512 T1 AT E2512T1 AT 80107181 T AT80107181 T AT 80107181T AT 80107181 T AT80107181 T AT 80107181T AT E2512 T1 ATE2512 T1 AT E2512T1
Authority
AT
Austria
Prior art keywords
polypeptides
processes
production
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT80107181T
Other languages
German (de)
English (en)
Inventor
Wilfried Bauer
Janos Dr. Pless
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of ATE2512T1 publication Critical patent/ATE2512T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT80107181T 1979-11-27 1980-11-19 Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung. ATE2512T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1052479 1979-11-27
CH457480 1980-06-13
EP80107181A EP0029579B1 (en) 1979-11-27 1980-11-19 Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use

Publications (1)

Publication Number Publication Date
ATE2512T1 true ATE2512T1 (de) 1983-03-15

Family

ID=25695798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT80107181T ATE2512T1 (de) 1979-11-27 1980-11-19 Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.

Country Status (25)

Country Link
US (1) US4395403A (enExample)
EP (1) EP0029579B1 (enExample)
JP (1) JPS5690048A (enExample)
AT (1) ATE2512T1 (enExample)
AU (1) AU543198B2 (enExample)
CA (1) CA1182109A (enExample)
CS (1) CS228140B2 (enExample)
CY (1) CY1327A (enExample)
DE (2) DE19375086I2 (enExample)
DK (1) DK150146C (enExample)
ES (2) ES8301463A1 (enExample)
FI (1) FI72981C (enExample)
GR (1) GR71636B (enExample)
HK (1) HK30686A (enExample)
HU (1) HU185920B (enExample)
IE (1) IE50571B1 (enExample)
IL (1) IL61561A (enExample)
KE (1) KE3606A (enExample)
LU (1) LU88344I2 (enExample)
MY (1) MY8500072A (enExample)
NL (1) NL930137I2 (enExample)
NZ (1) NZ195640A (enExample)
PH (1) PH22841A (enExample)
PT (1) PT72103B (enExample)
SG (1) SG8786G (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK81082A (da) * 1981-03-06 1982-09-07 Sandoz Ag Fremgangsmaade til fremstilling af polypeptider
CH655505B (enExample) * 1982-08-24 1986-04-30
US4663435A (en) * 1982-12-06 1987-05-05 Merck & Co., Inc. Bridged cyclic hexapeptide somatostatin analogs
FR2554347B1 (fr) * 1983-11-07 1986-10-03 Immunotech Sa Acide pressinique, ses derives aminoacides substitues et homologues de configuration d ainsi que les derives n- et c- terminal-substitues et leurs applications dans les domaines therapeutique, biologique ou immunologique
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
GB8423431D0 (en) * 1984-09-17 1984-10-24 Sandoz Ltd Organic compounds
US4650787A (en) * 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4904642A (en) * 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
JPH085913B2 (ja) * 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド 治療用ソマトスタチン同族体
GR862206B (en) * 1985-09-12 1986-12-31 Univ Tulane Therapeutic somatostatin analogs
NL8701143A (nl) * 1986-05-27 1987-12-16 Sandoz Ag Farmaceutische preparaten.
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
DE3726517A1 (de) * 1986-08-18 1988-03-03 Sandoz Ag Nasale zusammensetzungen, welche octreotid enthalten
GB8620035D0 (en) * 1986-08-18 1986-10-01 Sandoz Ltd Organic compounds
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
DE3790635B4 (de) * 1986-10-13 2007-11-22 Novartis Ag Verfahren zur Herstellung eines Peptidalkohols und Ausgangsverbindungen dafür
US4871717A (en) * 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
US5073541A (en) * 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
ZA895838B (en) * 1988-08-18 1991-03-27 Syntex Inc Pharmaceutical compounds
US5006510A (en) * 1989-06-20 1991-04-09 Ellis Wladislaw V Method for relieving chronic pain with a somatostatin analog composition
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5084443A (en) * 1989-12-04 1992-01-28 Biomeasure, Inc. Promoting expression of acetylcholine receptors with lhrh antagonist
EP0457888B1 (en) * 1989-12-08 1996-07-10 The Administrators of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
DE69229436T2 (de) * 1991-02-08 1999-11-25 Biomeasure, Inc. Verwendung von somatostatinanalogen zur behandlung von melanomen
US5504069A (en) * 1993-02-11 1996-04-02 Biomeasure, Inc. Inhibition of trauma-induced tumor growth
GB9402767D0 (en) * 1994-02-14 1994-04-06 Sandoz Ltd Improvements in or relating to organic compounds
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
EP0824103A1 (en) * 1996-08-13 1998-02-18 Chang-Shinn Su Method for synthesis of Tyr-3-octreotide
US6262229B1 (en) 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
AU8019898A (en) * 1997-05-13 1998-12-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome
AU7655098A (en) * 1997-05-13 1998-12-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Somatostatin and somatostatin agonists for decreasing body weight
US7026289B2 (en) * 1997-05-13 2006-04-11 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Method and compositions for treating hyperlipidemia and other conditions
ES2144357B1 (es) * 1998-01-29 2000-12-16 Lipotec Sa Procedimiento para la obtencion del analogo de somatostatina octreotide.
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
US6159935A (en) * 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
RU2196144C1 (ru) * 2001-05-14 2003-01-10 Самуков Владимир Васильевич Защищенные производные октреотида
NZ530007A (en) 2001-06-08 2006-02-24 Sod Conseils Rech Applic Somatostatin-dopamine chimeric analogues that retain both somatostatin and dopamine activity in vivo and display enhanced biological activity
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US6987167B2 (en) 2002-05-22 2006-01-17 Wockhardt Limited Process for production of the somatostatin analog, octreotide
US20040097419A1 (en) 2002-11-19 2004-05-20 Holger Petersen Organic compounds
DE04759123T1 (de) * 2003-04-07 2005-08-18 Novetide Ltd. Verfahren zur herstellung cyclischer peptide
JP4578470B2 (ja) 2003-04-22 2010-11-10 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ソマトスタチンベクター
ES2344657T3 (es) * 2004-10-04 2010-09-02 Novetide, Ltd. Procedimiento de intercambio de contraion para peptidos.
PT2359809T (pt) 2005-12-22 2019-11-04 Novartis Ag Formulação de libertação sustentada que compreende octreótido e dois ou mais polímeros poliláctido-co-glicólido
EP2013226A2 (en) * 2006-03-28 2009-01-14 Wockhardt Limited Processes for the preparation of octreotide
TW200819137A (en) * 2006-10-31 2008-05-01 Iner Aec Executive Yuan Method for preparation of lipid-spacer radical- reactions of functional group-peptide
US20090082259A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched octreotide
EP2172189A1 (en) 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
EP2213307A1 (en) 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
US8377891B2 (en) 2008-11-07 2013-02-19 Usv, Ltd. Process for synthesis of cyclic octapeptide
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20140296144A1 (en) 2011-09-30 2014-10-02 Mylan Laboratories, Ltd. Process for the preparation of octreotide acetate
CN103102390B (zh) * 2011-11-09 2015-01-28 杭州华津允上医药有限公司 一种奥曲肽的制备方法
WO2013132505A1 (en) 2012-03-09 2013-09-12 Natco Pharma Limited Improved process for preparation of octreotide by solution phase peptide synthesis
DK3007704T3 (da) 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Kombinationsterapi til akromegali
CN108395469A (zh) * 2018-02-01 2018-08-14 滨海吉尔多肽有限公司 一种假脯氨酸二肽的合成方法
GB202012334D0 (en) 2020-08-07 2020-09-23 Avon Polymer Prod Ltd Monitoring system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105603A (en) * 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4140767A (en) * 1977-12-01 1979-02-20 Merck & Co., Inc. Somatostatin analogs
US4139526A (en) * 1977-12-01 1979-02-13 Merck & Co., Inc. Somatostatin analogs
US4190648A (en) * 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4225472A (en) * 1979-05-29 1980-09-30 American Home Products Corporation Truncated somatostatin analogs
US4310518A (en) * 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4282143A (en) * 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone

Also Published As

Publication number Publication date
HK30686A (en) 1986-05-09
FI72981C (fi) 1987-08-10
GR71636B (enExample) 1983-06-20
PH22841A (en) 1989-01-19
SG8786G (en) 1987-03-27
JPS6351159B2 (enExample) 1988-10-13
DK150146B (da) 1986-12-15
ES497113A0 (es) 1982-12-01
LU88344I2 (fr) 1994-05-04
ES510751A0 (es) 1983-04-16
ES8301463A1 (es) 1982-12-01
DK501980A (da) 1981-05-28
CS228140B2 (en) 1984-05-14
AU6468880A (en) 1981-06-04
CA1182109A (en) 1985-02-05
KE3606A (en) 1986-03-17
NZ195640A (en) 1984-07-06
PT72103B (fr) 1982-01-28
EP0029579B1 (en) 1983-02-16
ES8305701A1 (es) 1983-04-16
PT72103A (fr) 1980-12-01
IE50571B1 (en) 1986-05-14
AU543198B2 (en) 1985-04-04
CY1327A (en) 1986-06-27
NL930137I1 (nl) 1993-11-01
HU185920B (en) 1985-04-28
DK150146C (da) 1987-06-01
DE19375086I2 (de) 2003-01-09
JPS5690048A (en) 1981-07-21
DE3062075D1 (en) 1983-03-24
FI72981B (fi) 1987-04-30
NL930137I2 (nl) 1997-02-03
IL61561A0 (en) 1980-12-31
EP0029579A1 (en) 1981-06-03
MY8500072A (en) 1985-12-31
IL61561A (en) 1985-02-28
FI803634L (fi) 1981-05-28
US4395403A (en) 1983-07-26
IE802452L (en) 1981-05-27

Similar Documents

Publication Publication Date Title
ATE2512T1 (de) Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.
ATE56728T1 (de) Neue polypeptide mit alpha-amylase-hemmender wirkung, verfahren zu deren herstellung, deren verwendung und pharmazeutische praeparate.
IL60185A (en) 6 beta,7 beta;15,16-dimethylene-1,4-androstadien-3-ones,process for their production and pharmaceutical preparations containing them
ATE19400T1 (de) N-(2,2,2-trifluorethyl)-n-alkylazolyloxyessigs|ureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide sowie neue zwischenprodukte zu ihrer herstellung.
ATE8387T1 (de) Oxindol-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel mit neuroanaboler wirkung.
ES8302675A1 (es) "procedimiento para la preparacion de 1,2 benzisoxazoloxietilaminas".
ATE26577T1 (de) 1-0-alkyl-3-amino-propan-1.2-diol-2-0phospholipide, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten.
ATE107311T1 (de) Modifizierte splenopentine, verfahren zu ihrer herstellung und ihre verwendung.
ATE115565T1 (de) 2-halogensubstituierte n-indolylethyl- sulfonsäureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
DE3874251D1 (de) Guanidin-verbindungen, die ein tetraphenylboration enthalten, verfahren, um diese zu erhalten und verwendung dieser verbindungen in der peptidsynthese.
ATE32063T1 (de) Iminosulfonamide und verfahren zu ihrer herstellung, die pharmazeutische praeparate solche verbindungen enthalten, sowie die verbindungen zur verwendung.
ATE62688T1 (de) Benzylaminoaryl-dihydropyridinelactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ATE226T1 (de) N-iso-propyl-s-(1,6-dihyd ro-6-(thi)oxo-pyridazin(1 )-yl-methyl)-thiolphosphorsaeure-esteramide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel.
EP0299397A3 (de) Peptide mit vasorelaxierender, natriuretischer und diuretischer Wirkung, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung
ATE112268T1 (de) 2-amino-1,2,3,4-tetrahydroisochinolin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE10932T1 (de) Substituierte oxocarbonsaeuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel.
ATE39046T1 (de) Proteinhydrolysate, verfahren zu ihrer herstellung und arzneimittel, die diese hydrolysate enthalten.
ATE11406T1 (de) 6,7,8,9-tetrahydro-3h-benz(e)indolaminderivate, verfahren zu ihrer herstellung und dabei verwendete zwischenverbindungen und pharmazeutische zubereitungen, die die indolaminderivate enthalten.